Inhibikase Therapeutics, Inc. will present an update on the of the 201 Trial evaluating risvodetinib at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal. Dr. Werner's presentation entitled "The 201 Trial in Untreated Parkinson's Disease" will be presented at the Symposium on "Advances in Parkinson's Disease and Dementia with Lewy Body Drug Development" to be held on March 9, 2024 at 6:25 pm WEST /1:25 pm EDT. The 201 Trial is evaluating 50, 100 and 200 mg once daily doses of risvo in untreated Parkinson's disease.

As of February 24, 2024, 32 sites are open and actively evaluating prospective trial participants. 59 participants have been enrolled, 19 prospective participants are in medical screening and 54 potential participants are being evaluated for suitability to initiate medical screening. Participants experience in the trial appears to be positive, as clinician and patient impression of disease status or severity is not changing over the 12 week course of dosing.

Motor and non-motor functional assessments cannot be interpreted from blinded results. Depending on the date of enrollment of the last participant, top line results from the 201 Trial might be reported in the second-half of 2024.